Last reviewed · How we verify
fludarabine, cyclophosphamide, doxorubicin, rituximab
fludarabine, cyclophosphamide, doxorubicin, rituximab is a Small molecule drug developed by A.O. Ospedale Papa Giovanni XXIII. It is currently FDA-approved.
At a glance
| Generic name | fludarabine, cyclophosphamide, doxorubicin, rituximab |
|---|---|
| Sponsor | A.O. Ospedale Papa Giovanni XXIII |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (PHASE3)
- Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (PHASE3)
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment (PHASE3)
- Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (PHASE3)
- Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (PHASE1, PHASE2)
- Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A (PHASE3)
- Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fludarabine, cyclophosphamide, doxorubicin, rituximab CI brief — competitive landscape report
- fludarabine, cyclophosphamide, doxorubicin, rituximab updates RSS · CI watch RSS
- A.O. Ospedale Papa Giovanni XXIII portfolio CI
Frequently asked questions about fludarabine, cyclophosphamide, doxorubicin, rituximab
What is fludarabine, cyclophosphamide, doxorubicin, rituximab?
fludarabine, cyclophosphamide, doxorubicin, rituximab is a Small molecule drug developed by A.O. Ospedale Papa Giovanni XXIII.
Who makes fludarabine, cyclophosphamide, doxorubicin, rituximab?
fludarabine, cyclophosphamide, doxorubicin, rituximab is developed and marketed by A.O. Ospedale Papa Giovanni XXIII (see full A.O. Ospedale Papa Giovanni XXIII pipeline at /company/a-o-ospedale-papa-giovanni-xxiii).
What development phase is fludarabine, cyclophosphamide, doxorubicin, rituximab in?
fludarabine, cyclophosphamide, doxorubicin, rituximab is FDA-approved (marketed).